Allison Berger

5.0k total citations
69 papers, 2.1k citations indexed

About

Allison Berger is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Allison Berger has authored 69 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 25 papers in Oncology and 16 papers in Immunology. Recurrent topics in Allison Berger's work include Ubiquitin and proteasome pathways (45 papers), Protein Degradation and Inhibitors (17 papers) and Peptidase Inhibition and Analysis (11 papers). Allison Berger is often cited by papers focused on Ubiquitin and proteasome pathways (45 papers), Protein Degradation and Inhibitors (17 papers) and Peptidase Inhibition and Analysis (11 papers). Allison Berger collaborates with scholars based in United States, Japan and Canada. Allison Berger's co-authors include Jie Yu, Mark Manfredi, Lawrence R. Dick, Joshua M. Kaplan, Anne C. Hart, Mark Rolfe, Michael A. Milhollen, Bret Bannerman, Paul Hales and Erik Kupperman and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Allison Berger

66 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Allison Berger United States 21 1.6k 779 452 241 231 69 2.1k
Yosef Landesman United States 33 2.5k 1.6× 935 1.2× 640 1.4× 303 1.3× 232 1.0× 171 3.2k
Louise Bergeron United States 11 2.3k 1.4× 403 0.5× 361 0.8× 214 0.9× 352 1.5× 14 2.6k
Eric Wang United States 22 3.2k 1.9× 435 0.6× 1.0k 2.3× 320 1.3× 240 1.0× 36 3.8k
Joseph M. Amann United States 28 1.8k 1.1× 825 1.1× 346 0.8× 426 1.8× 173 0.7× 53 2.7k
Joseph Gera United States 28 2.4k 1.5× 592 0.8× 474 1.0× 396 1.6× 376 1.6× 60 3.0k
Marianne Terndrup Pedersen Denmark 17 1.9k 1.1× 441 0.6× 246 0.5× 188 0.8× 346 1.5× 26 2.6k
Andrew Pierce United Kingdom 23 1.3k 0.8× 423 0.5× 575 1.3× 270 1.1× 254 1.1× 69 2.2k
Rekha Rao United States 25 1.8k 1.1× 401 0.5× 506 1.1× 155 0.6× 170 0.7× 49 2.2k
Florian Grebien Austria 25 1.3k 0.8× 450 0.6× 793 1.8× 195 0.8× 323 1.4× 62 2.4k
Christy C. Ong United States 9 1.3k 0.8× 510 0.7× 206 0.5× 195 0.8× 507 2.2× 12 1.8k

Countries citing papers authored by Allison Berger

Since Specialization
Citations

This map shows the geographic impact of Allison Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Berger more than expected).

Fields of papers citing papers by Allison Berger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Berger. The network helps show where Allison Berger may publish in the future.

Co-authorship network of co-authors of Allison Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Berger. A scholar is included among the top collaborators of Allison Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Berger. Allison Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Narayanan, Jayanth S. Shankara, et al.. (2024). Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment. Molecular Cancer Therapeutics. 23(11). 1597–1612. 2 indexed citations
2.
Wang, Xiaoguang, Jing Wang, Allison Berger, et al.. (2023). Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia. Leukemia. 37(6). 1324–1335. 7 indexed citations
3.
Liu, Tingting, Tycel Phillips, Geoffrey Shouse, et al.. (2023). T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia. Molecular Cancer Therapeutics. 22(9). 1040–1051. 8 indexed citations
4.
Derry, Jonathan M.J., Jason P. Frazier, Marc Grenley, et al.. (2023). Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment. Clinical Cancer Research. 29(18). 3813–3825. 17 indexed citations
5.
Li, Jinyang, Fangxue Yan, Jun Gui, et al.. (2022). Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment. Cancer Immunology Research. 10(12). 1490–1505. 10 indexed citations
6.
7.
Dudek, Arkadiusz Z., Dejan Juric, Afshin Dowlati, et al.. (2021). 476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results. Regular and Young Investigator Award Abstracts. A505–A506. 10 indexed citations
8.
Darabos, Katie, Allison Berger, Lamia P. Barakat, & Lisa A. Schwartz. (2021). Cancer-Related Decision-Making Among Adolescents, Young Adults, Caregivers, and Oncology Providers. Qualitative Health Research. 31(13). 2355–2363. 18 indexed citations
9.
Wong, Kit Man, Heather M. Selby, Aik Choon Tan, et al.. (2016). Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). Investigational New Drugs. 35(1). 11–25. 16 indexed citations
10.
Shah, Jatin J., Andrzej Jakubowiak, Owen A. O’Connor, et al.. (2015). Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 22(1). 34–43. 162 indexed citations
11.
Sarantopoulos, John, Geoffrey I. Shapiro, Roger B. Cohen, et al.. (2015). Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 847–857. 139 indexed citations
12.
Danilova, Olga V., et al.. (2015). Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells. Leukemia & lymphoma. 56(5). 1566–1569. 10 indexed citations
13.
Berger, Allison, et al.. (2015). Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. Cell Death and Disease. 6(7). e1807–e1807. 47 indexed citations
14.
Nawrocki, Steffan T., Kevin R. Kelly, Peter G. Smith, et al.. (2013). Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer. Clinical Cancer Research. 19(13). 3577–3590. 89 indexed citations
15.
Jazaeri, Amir A., Etsuko Shibata, Jong-Hoon Park, et al.. (2013). Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924. Molecular Cancer Therapeutics. 12(10). 1958–1967. 58 indexed citations
16.
Tompkins, Van S., Alicia K. Olivier, Ramakrishna Sompallae, et al.. (2013). 18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer Journal. 3(11). e165–e165. 22 indexed citations
17.
Bannerman, Bret, Ling Xu, Matthew D. Jones, et al.. (2011). Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemotherapy and Pharmacology. 68(5). 1145–1154. 32 indexed citations
18.
Kupperman, Erik, Edmund C. Lee, Yueying Cao, et al.. (2010). Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer. Cancer Research. 70(5). 1970–1980. 409 indexed citations
19.
Rolfe, Mark, et al.. (2007). Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer. Molecular Cancer Therapeutics. 6. 1 indexed citations
20.
Weiss, Susan R.B., et al.. (1993). Cross-tolerance between carbamazepine and valproate on amygdala-kindled seizures. Epilepsy Research. 16(1). 37–44. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yosef Landesman Breakdown of academic impact, for papers by Louise Bergeron Breakdown of academic impact, for papers by Eric Wang Breakdown of academic impact, for papers by Joseph M. Amann Breakdown of academic impact, for papers by Joseph Gera Breakdown of academic impact, for papers by Marianne Terndrup Pedersen Breakdown of academic impact, for papers by Andrew Pierce Breakdown of academic impact, for papers by Rekha Rao Breakdown of academic impact, for papers by Florian Grebien Breakdown of academic impact, for papers by Christy C. Ong
Rankless by CCL
2026